title: Treatment patterns and outcomes with subcutaneous bortezomib in patients with relapsed mantle cell lymphoma: a retrospective, observational study of patient medical records from US community oncology practices.
authors.affiliation: a Lymphoma Division, Blood and Marrow Transplantation Program, John Theurer Cancer Center , Hackensack University Medical Center , Hackensack , NJ , USA.
authors.forename: Alan P
authors.initials: AP
authors.lastname: Skarbnik
authors.affiliation: b Millennium Pharmaceuticals Inc , Cambridge , MA , USA.
authors.forename: Esprit
authors.initials: E
authors.lastname: Ma
authors.affiliation: c Groupe d'analyse, Ltée , Montreal , QC , Canada.
authors.forename: Marie-Hélène
authors.initials: MH
authors.lastname: Lafeuille
authors.affiliation: c Groupe d'analyse, Ltée , Montreal , QC , Canada.
authors.forename: Jonathan
authors.initials: J
authors.lastname: Fortier
authors.affiliation: a Lymphoma Division, Blood and Marrow Transplantation Program, John Theurer Cancer Center , Hackensack University Medical Center , Hackensack , NJ , USA.
authors.forename: Tatyana
authors.initials: T
authors.lastname: Feldman
authors.affiliation: d Analysis Group, Inc , Boston , MA , USA.
authors.forename: Mei Sheng
authors.initials: MS
authors.lastname: Duh
authors.affiliation: b Millennium Pharmaceuticals Inc , Cambridge , MA , USA.
authors.forename: Helgi
authors.initials: H
authors.lastname: van de Velde
authors.affiliation: b Millennium Pharmaceuticals Inc , Cambridge , MA , USA.
authors.forename: Liviu
authors.initials: L
authors.lastname: Niculescu
authors.affiliation: b Millennium Pharmaceuticals Inc , Cambridge , MA , USA.
authors.forename: Vijayveer
authors.initials: V
authors.lastname: Bonthapally
authors.affiliation: a Lymphoma Division, Blood and Marrow Transplantation Program, John Theurer Cancer Center , Hackensack University Medical Center , Hackensack , NJ , USA.
authors.forename: André
authors.initials: A
authors.lastname: Goy
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D000069286:Bortezomib / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy* / Q000453:epidemiology* / Q000473:pathology; D008297:Male; D010818:Practice Patterns, Physicians'; D061988:Proteasome Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D012008:Recurrence; D019233:Retreatment; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
chemical_list: D000970:Antineoplastic Agents; D061988:Proteasome Inhibitors; D000069286:Bortezomib